Mandy Jackson

Mandy Jackson

Managing Editor, US Commercial News

San Diego, CA

Mandy reports on daily biopharma developments, writes feature stories and produces Scrip's Finance Watch column. She covers finance, start-ups, dealmaking, clinical trial results, quarterly earnings reports, commercial competition and corporate strategy. Mandy regularly interviews everyone from big pharma CEOs to biotech start-up founders, enhancing her expertise on industry trends and market dynamics. She also is interested in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, diversity in the biopharma industry and novel approaches to drug development. She has been a business reporter since 2000, covering biopharma, biotech law and commercial real estate.

Latest from Mandy Jackson

Sionna IPO Grosses $191m To Compete With Vertex In CF

Sionna essentially doubled its cash on hand with its initial public offering to go up against a formidable competitor in cystic fibrosis with novel medicines applicable to a broad population.

Bristol’s 2025 Guidance Falls Short, But CEO Boerner Warned This Was Coming

Boerner warned a year ago that BMS may see its revenue falter in the middle of this decade and the company’s 2025 guidance suggests that will happen this year after 2024 beat consensus.

Genmab Has First Wholly Owned Antibodies In Phase III, Hunts For More

CMO Tahamtan Ahmadi told Scrip that Genmab hopes to do a deal in 2025 like its ProfoundBio acquisition in 2024 as the company seeks to develop more antibodies entirely on its own.

BMS Enters A Catalyst-Rich Era Full Of Both LOEs And New Launches

Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.

Amgen Optimistic About Growth, Despite Denosumab Biosimilars, Potential Tariffs

Amgen saw revenue rise 19% to $33.4bn in 2024 and said revenue should grow to $34.3bn-$35.7bn in 2025 despite losing exclusivity for its biggest franchise – Prolia and Xgeva (denosumab) – this year.

Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ In R&D

Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.